EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

“Prospective Clinical Validation of an Optimized TMD Screening Tool: Results of a Two-Stage Validation Process”

Raphael Matthias Faulhaber iD, Ingrid Peroz, Simon Peroz

Clinical Oral Investigations · 11.07.2026 · 30 (8)

DOI: 10.1007/s00784-026-06995-5 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Clinical Oral Investigations, online erschienen am 11.07.2026. Verfasst von Raphael Matthias Faulhaber und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Prosthodontics, Geriatric Dentistry and Functional Sciences, Charité Berlin, Berlin, Germany. raphael.faulhaber@charite.de. Hauptthemen laut MEDLINE: Temporomandibular Joint Disorders, Mass Screening. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim of this prospective validation study was to evaluate the diagnostic performance of a newly developed TMD screening tool of the German Society for Craniomandibular Function (DGFDT) in its statistically optimized scoring version as well as in a clinically modified version, and to compare both with established screening instruments. Materials and methods A total of 121 consecutive patients treated at Charité – Universitätsmedizin Berlin were examined using the DC/TMD as reference standard. The DGFDT TMD screening tool was compared with the “CMD-Kurzbefund” according to Ahlers and Jakstat and the three TMD-related screening questions according to Lövgren et al. In addition to the primary analysis, a predefined sensitivity analysis excluded cases with isolated, painless temporomandibular joint noises ( n = 110). Diagnostic performance metrics were calculated with 95% confidence intervals using exact binomial methods.

Results

In the primary analysis, the statistically optimized version of the TMD screening tool achieved both sensitivity and specificity of 100.0%, representing the statistical optimum. The clinically modified DGFDT version achieved a sensitivity of 84.6% while maintaining a specificity of 100.0%. In the predefined sensitivity analysis, its sensitivity increased to 98.1%, while specificity remained 100.0%. Established comparator instruments showed lower sensitivities in the primary analysis (“CMD-Kurzbefund”: 73.8%; 3Q/TMD: 75.4%) and in the sensitivity analysis (“CMD-Kurzbefund”: 85.2%; 3Q/TMD: 90.7%).

Conclusions

Both DGFDT screening versions demonstrated superior diagnostic performance in this single-center cohort. The clinically modified version represents a consensus- and evidence-based alternative that reduces the impact of isolated, painless temporomandibular joint noises without relevant loss of diagnostic accuracy. Clinical Relevance The DGFDT TMD screening tool provides a standardized and practical instrument for early clinical detection of temporomandibular disorders and may contribute to the standardization of TMD diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Temporomandibular Joint DisordersMass ScreeningHumansProspective StudiesFemaleSensitivity and SpecificityMaleMiddle AgedAdult

Stichwörter der Autor:innen

Diagnostic accuracyEvidence-based diagnosticsTMD screeningTemporomandibular disorderValidation study

Autor:innen und Institutionen

  • Department of Prosthodontics, Geriatric Dentistry and Functional Sciences, Charité Berlin, Berlin, Germany. raphael.faulhaber@charite.de.
  • Department of Prosthodontics, Geriatric Dentistry and Functional Sciences, Charité - Universitätsmedizin Berlin, Berlin, Germany. raphael.faulhaber@charite.de.
  • Department of Prosthodontics, Geriatric Dentistry and Functional Sciences, Charité Berlin, Berlin, Germany.

ORCID-Profile: Raphael Matthias Faulhaber

Förderung

  • Charité - Universitätsmedizin Berlin

Zitieren

APA

Faulhaber, R. M., Peroz, I., & Peroz, S. (2026). “Prospective Clinical Validation of an Optimized TMD Screening Tool: Results of a Two-Stage Validation Process”. Clinical Oral Investigations, 30(8). https://doi.org/10.1007/s00784-026-06995-5

Vancouver

Faulhaber RM, Peroz I, Peroz S. “Prospective Clinical Validation of an Optimized TMD Screening Tool: Results of a Two-Stage Validation Process”. Clinical Oral Investigations. 2026;30(8). doi:10.1007/s00784-026-06995-5

BibTeX
@article{Faulhaber2026,
  author = {Faulhaber, Raphael Matthias and Peroz, Ingrid and Peroz, Simon},
  title = {“Prospective Clinical Validation of an Optimized TMD Screening Tool: Results of a Two-Stage Validation Process”},
  journal = {Clinical Oral Investigations},
  year = {2026},
  volume = {30},
  number = {8},
  doi = {10.1007/s00784-026-06995-5}
}
Kostenlos starten →